NEW YORK (GenomeWeb) – Agilent Technologies and Seahorse Bioscience announced after the close of the market on Wednesday that they have signed a definitive agreement under which Agilent will acquire Seahorse for $235 million in cash. 

Seahorse is based in Billerica, Massachusetts, and its technology enables scientists to better understand cell health, function, and signaling, as well as investigate the impact of the introduction of a specific drug on the cell by providing real-time kinetics "to unlock essential cellular bioenergetics data," the firms said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.